Schizophrenia Clinical Trials in Los Angeles

Showing 21-40 of 98 trials

Enhancing Cognitive Training Through Exercise Following a First Schizophrenia Episode

NCT02823041

This is a confirmatory randomized controlled trial of the efficacy of a novel intervention combining neuroplasticity-based cognitive training with aerobic exercise, compared to the same systematic cognitive training alone. Treatment occurs for 6 months after randomization, with a followup assessment at 12 months. The investigators hypothesize that combining neuroplasticity-based computerized cognitive training and neurotrophin-enhancing physical exercise will produce neurotrophin increases and cognitive and functional improvements, even relative to cognitive training alone. The investigators target the period shortly after a first episode of schizophrenia to maximize the generalization of cognitive improvement to functional outcome, before chronic disability is established.

SchizophreniaSchizophreniform DisorderSchizoaffective Disorder

University of California, Los Angeles100 participantsStarted Oct 2016

Los Angeles, California, United States

COMPLETEDPHASE4< 1 mile

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

NCT01451736

This study will determine the efficacy of oral risperidone (Risperdal) versus long-acting injectable paliperidone palmitate (Invega Sustenna) in treating people with first-episode schizophrenia.

Schizophrenia (Recent-onset)

University of California, Los Angeles146 participantsStarted Oct 2011

Los Angeles, California, United States

Enhancing Cognitive Training Through Exercise Following a First Schizophrenia Episode

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

Schizophrenia Trials in Other Cities

Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia

A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

Relapse Prevention Study in Patients With Schizophrenia

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

Project Bridge: Peer Health Navigator Intervention

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Relative Bioavailability of LY03010 Compared to Listed Drug

An Integrated Program for the Treatment of First Episode of Psychosis

Comparative Bioavailability of Risperidone

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

Comparative Bioavailability of Risperidone.

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

Improving Cognition Via Exercise in Schizophrenia

Other Conditions in Los Angeles